Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.
about
Interventions for latent autoimmune diabetes (LADA) in adultsRandomized, controlled, parallel-group prospective study to investigate the clinical effectiveness of early insulin treatment in patients with latent autoimmune diabetes in adultsType 1 1/2 diabetes: myth or reality?β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up.Current knowledge of Japanese type 1 diabetic syndrome.Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetesAutoimmune diabetes: more than just one flavor?Type 1 diabetes as a model for prediction and diagnosis.Immunomodulatory therapy of human type 1 diabetes: lessons from the mouseAn islet-cell protein tyrosine phosphatase is a likely precursor to the 37-kDa autoantigen in type 1 diabetes: human and macaque sequences, tissue distribution, unique and shared epitopes, and predictive autoantibodies.Beta-cell protection and therapy for latent autoimmune diabetes in adults.Diabetes and beta cell function: from mechanisms to evaluation and clinical implications.Latent autoimmune diabetes of the adult: current knowledge and uncertaintyLatent autoimmune diabetes in adults (LADA) in Asian and European populations.Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study.Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).Non-insulin dependent diabetes mellitus in African-American youths of Arkansas.Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).Recognizing and Appropriately Treating Latent Autoimmune Diabetes in Adults.Latent Autoimmune Diabetes in Adults: Current Status and New Horizons.
P2860
Q24234365-8AE57FCC-6B52-45DF-A6DE-BB8C9C06DB15Q33354779-59B9D772-D03E-464B-BE46-05DE83BB3167Q33537671-81E379CB-4BBB-4D1A-AE3C-278F97C4E7D4Q34497677-29774541-C933-40C6-ADF3-F241C9DA4203Q34979242-D90A599C-489B-46B2-BCDD-9C0AC5D5C7D8Q35010284-9F555CF4-0770-480B-8F0B-145195AFF409Q35847881-F5A76DAE-A002-4479-8B67-6E431C04563EQ35934762-3DACBD96-8576-4B42-B9A5-4C91EB0BCE60Q36167431-D67B1887-0D1B-4ABB-A0DC-F33921BE9E82Q36853549-5DF5E1B8-09E4-44DF-959D-2A054D36B9A4Q37624274-62F6660F-6CD2-4B7C-A61F-248122813A09Q38165184-3FD568DB-8FF4-46E6-A5FA-BB504650CD1AQ38324198-7CE23B00-357A-46E7-94D1-D907040C3A4AQ39136099-9FE2F9B6-2F25-44CC-B711-D04B2D27DD9DQ39550637-B1E63D14-0856-48A9-9520-131CD92D93D4Q40524112-F04BD138-EC66-4124-BBA6-02D74F3BE047Q41716381-C0B1A705-2902-433D-9077-56E978A1D2A5Q42371744-DDA4CDE5-94A7-4B89-A721-0FCF1798AE79Q42748372-6A7681E2-76D0-400E-AEF7-9BC73C5420CAQ55397117-A13D0409-811D-4967-8CF2-6926769FF12E
P2860
Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Small doses of subcutaneous in ...... th clinical features of NIDDM.
@en
Small doses of subcutaneous in ...... th clinical features of NIDDM.
@nl
type
label
Small doses of subcutaneous in ...... th clinical features of NIDDM.
@en
Small doses of subcutaneous in ...... th clinical features of NIDDM.
@nl
prefLabel
Small doses of subcutaneous in ...... th clinical features of NIDDM.
@en
Small doses of subcutaneous in ...... th clinical features of NIDDM.
@nl
P2093
P356
P1433
P1476
Small doses of subcutaneous in ...... th clinical features of NIDDM.
@en
P2093
P304
P356
10.2337/DIAB.45.5.622
P407
P577
1996-05-01T00:00:00Z